文献速递免疫规划

基于脂质A的TLR4模拟佐剂有效增强鼠疫耶尔森菌rF-V1亚单位疫苗在小鼠攻毒模型中的保护效果

A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model.
PubMed 文献 · Vaccine · 2018-05-31

研究通过细菌酶组合化学合成新型TLR4配体佐剂BECC438,经体外筛选显示其 innate 免疫激活谱与PHAD相当;在小鼠初免-加强接种rF1-V后,BECC438诱导的rF1-V特异性总IgG水平高于PHAD,并激发平衡的IgG1/IgG2c应答,保护小鼠抵抗致死性鼠疫耶尔森菌攻毒。

要点

  • BECC438经体外筛选显示与PHAD相当的先天免疫激活特征。
  • BECC438增强rF1-V特异性总IgG应答,初免和加强后均高于PHAD。
  • BECC438诱导平衡IgG1/IgG2c应答并保护小鼠抵抗致死性鼠疫耶尔森菌攻毒。

核心结论

  • BECC438在体外诱导与PHAD相似的细胞因子谱,在小鼠体内诱导高抗原特异性免疫滴度和TH1相关IgG2c免疫偏移,并保护小鼠抵抗致死性鼠疫耶尔森菌攻毒。

研究设计与样本

  • 使用结构-活性关系(SAR)模型和细菌酶组合化学(BECC)合成TLR4配体佐剂BECC438;体外筛选包括NFκB活化和细胞因子产生、原代人PBMC细胞因子产生、原代人单核细胞衍生树突状细胞表面共刺激标志物上调;体内用鼠疫耶尔森菌保护性抗原rF1-V在小鼠初免-加强接种后行致死性攻毒。

主要发现

  • BECC438在体外产生与PHAD相当的先天免疫激活谱。
  • BECC438在初免和加强后均刺激产生比PHAD更高水平的rF1-V特异性总IgG。
  • BECC438与PHAD相似,引发平衡的IgG1/IgG2c应答,指示活跃的TH2/TH1驱动免疫。
  • BECC438保护小鼠抵抗致死性鼠疫耶尔森菌攻毒。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination can significantly reduce worldwide morbidity and mortality to infectious diseases, thereby reducing the health burden as a result of microbial infections. Effective vaccines contain three components: a delivery system, an antigenic component of the pathogen, and an adjuvant. With the growing use of purely recombinant or synthetic antigens, there is a need to develop novel adjuvants that enhance the protective efficacy of a vaccine against infection. Using a structure-activity relationship (SAR) model, we describe here the synthesis of a novel TLR4 ligand adjuvant compound, BECC438, by bacterial enzymatic combinatorial chemistry (BECC). This compound was identified using an in vitro screening pipeline consisting of (i) NFκB activation and cytokine production by immortalized cell lines, (ii) cytokine production by primary human PBMCs, and (iii) upregulation of surface costimulatory markers by primary human monocyte-derived dendritic cells. Using this SAR screening regimen, BECC438 was shown to produce an innate immune activation profile comparable to the well-characterized TLR4 agonist adjuvant compound, phosphorylated hexa-acyl disaccharide (PHAD). To evaluate the in vivo adjuvant activity of BECC438, we used the known protective Yersinia pestis (Yp) antigen, rF1-V, in a murine prime-boost vaccination schedule followed by lethal challenge. In addition to providing protection from lethal challenge, BECC438 stimulated production of higher levels of rF1-V-specific total IgG as compared to PHAD after both prime and boost vaccinations. Similar to PHAD, BECC438 elicited a balanced IgG1/IgG2c response, indicative of active TH2/TH1-driven immunity. These data demonstrate that the novel BECC-derived TLR4L adjuvant, BECC438, elicits cytokine profiles in vitro similar to PHAD, induces high antigen-specific immune titers and a TH1-associated IgG2c immune titer skew, and protects mice against a lethal Yp challenge.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gregg KA, Harberts E, Gardner FM, et al. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model. Vaccine. 2018. PMID: 29861179. doi:10.1016/j.vaccine.2018.05.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。